drugset / Trial / NCT04812483
Immunomodulation With Eltrombopag in ITP
Phase 2
Completed
2 enrolled
University Children's Hospital Basel
Novartis Pharmaceuticals · collabStiftung zur Förderung medizinischer und biologischer Forschung · collabUniversity of Erlangen-Nürnberg, Department of Biology · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The study aims to investigate immunomodulatory effects of eltrombopag combined with dexamethasone in young and midlife adult patients with newly diagnosed primary Immune thrombocytopenia (ITP).
Timeline
- Start
- 2022-09-01
- Primary completion
- 2024-04-11
- Completion
- 2024-04-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dexamethasone | Small molecule | 40 mg | Oral |
| Subject | Eltrombopag | Small molecule | 50 mg | Oral |